In Brief: Graham-Field/Everest & Jennings
This article was originally published in The Gray Sheet
Executive Summary
Graham-Field/Everest & Jennings: Modify terms of merger agreement announced June 17 ("The Gray Sheet" June 24, p. 9). Under the revised agreement, stockholders of Everest and Jennings will receive one share of Graham-Field common stock in exchange for 2.857 shares of Everest & Jennings common stock; the $14.4 mil. in cash to be paid to holders of E&J common stock under the previous agreement has been eliminated. Including E&J outstanding shares, Graham-Field will issue approximately 2.5 mil. shares for the acquisition. The merger ratio is subject to adjustment so that the value of E&J common stock does not exceed $5.50 per share as of the closing date. The merger is expected to close in November...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.